Incorporation of therapeutic agents that inhibit the function of the hormone PRL or the PRLR receptor with those targeting the various signal transduction pathways, including those resulting from activation of HER2 could improve effectiveness in reversing resistance in breast cancer. Here, PRL is linked to breast cancer.